Display options
Cite
Rajzer M, Wojciechowska W, Kameczura T, et al. The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases. Arch Med Sci. 2016;13(4):760-770doi: 10.5114/aoms.2016.58825.
Rajzer, M., Wojciechowska, W., Kameczura, T., Olszanecka, A., Fedak, D., Terlecki, M., Kawecka-Jaszcz, K., & Czarnecka, D. (2017). The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases. Archives of medical science : AMS, 13(4), 760-770. https://doi.org/10.5114/aoms.2016.58825
Rajzer, Marek, et al. "The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases." Archives of medical science : AMS vol. 13,4 (2017): 760-770. doi: https://doi.org/10.5114/aoms.2016.58825
Rajzer M, Wojciechowska W, Kameczura T, Olszanecka A, Fedak D, Terlecki M, Kawecka-Jaszcz K, Czarnecka D. The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases. Arch Med Sci. 2017 Jun;13(4):760-770. doi: 10.5114/aoms.2016.58825. Epub 2016 Mar 23. PMID: 28721143; PMCID: PMC5510502.
Copy Download .nbib Format: NLM
Share it on

Arch Med Sci. 2017 Jun;13(4):760-770. doi: 10.5114/aoms.2016.58825. Epub 2016 Mar 23.

The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases.

Archives of medical science : AMS

Marek Rajzer, Wiktoria Wojciechowska, Tomasz Kameczura, Agnieszka Olszanecka, Danuta Fedak, Michał Terlecki, Kalina Kawecka-Jaszcz, Danuta Czarnecka

Affiliations

  1. First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University, Medical College, Krakow, Poland.
  2. Chair of Electroradiology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.
  3. Chair of Clinical Biochemistry and Diagnostics, Department of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland.

PMID: 28721143 PMCID: PMC5510502 DOI: 10.5114/aoms.2016.58825

Abstract

INTRODUCTION: The aim of the study was to assess the arterial stiffness and serum levels of selected metalloproteinases (MMPs) in hypertensive patients and their changes following antihypertensive therapy.

MATERIAL AND METHODS: The study group consisted of 95 patients with essential arterial hypertension (HT) stage 1 or 2 (mean age: 53.1 ±13.0 years). The control group consisted of 31 normotensives of the same age range. Hypertension patients were randomized to one of the following monotherapies for 6 months: quinapril, losartan, amlodipine, hydrochlorothiazide or bisoprolol. Carotid-femoral pulse wave velocity (PWV) was measured using a Complior device. Serum concentrations of MMPs (proMMP-1, MMP-2, MMP-3, MMP-9) and plasma concentration of tissue inhibitor of MMPs (TIMP-1) were measured using ELISA.

RESULTS: Pulse wave velocity and serum concentrations of MMP-2 and MMP-9 were higher in HT patients than in the control group. In HT patients PWV was significantly associated (

CONCLUSIONS: In patients with arterial hypertension, beside age and systolic blood pressure, the determinants of arterial stiffness include serum MMP-3 concentration. For drugs compared in the study with the same hypotensive effect obtained, the arterial stiffness reduction effect is not dependent on the drug used. Systolic blood pressure is one of the independent factors responsible for the reduction of arterial stiffness in the course of antihypertensive treatment.

Keywords: antihypertensive treatment; arterial hypertension; arterial stiffness; matrix metalloproteinases

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Hypertens Res. 2007 Oct;30(10):959-63 - PubMed
  2. Hypertension. 2002 Aug;40(2):136-41 - PubMed
  3. Lipids Health Dis. 2014 Aug 21;13:135 - PubMed
  4. Arch Med Sci. 2015 Mar 16;11(1):85-91 - PubMed
  5. Circulation. 1998 Aug 11;98 (6):535-40 - PubMed
  6. Circulation. 2001 Feb 20;103(7):987-92 - PubMed
  7. Clin Exp Hypertens. 2006 Jul;28(5):511-20 - PubMed
  8. Hypertension. 1995 Sep;26(3):485-90 - PubMed
  9. J Clin Invest. 2002 Sep;110(5):625-32 - PubMed
  10. Int J Cardiol. 2000 Aug;75(1):43-7 - PubMed
  11. J Hum Hypertens. 2003 Feb;17 (2):119-24 - PubMed
  12. Eur Heart J. 2006 Nov;27(21):2588-605 - PubMed
  13. Hypertension. 2008 Jun;51(6):1617-23 - PubMed
  14. Hypertension. 2003 May;41(5):1021-6 - PubMed
  15. J Hypertens. 2005 Apr;23(4):697-701 - PubMed
  16. Apoptosis. 2001 Dec;6(6):479-82 - PubMed
  17. J Nephrol. 2007 Jul-Aug;20(4):444-52 - PubMed
  18. Am J Hypertens. 2003 Jun;16(6):439-44 - PubMed
  19. Eur Heart J. 2010 Oct;31(19):2338-50 - PubMed
  20. Am J Hypertens. 2004 Sep;17(9):764-9 - PubMed
  21. J Hum Hypertens. 2006 Nov;20(11):867-73 - PubMed
  22. Hypertension. 2007 Jun;49(6):1271-7 - PubMed
  23. Hypertension. 2005 Jun;45(6):1050-5 - PubMed
  24. Thromb Res. 2008;121(4):543-8 - PubMed
  25. Clin Exp Pharmacol Physiol. 2001 Dec;28(12 ):1040-3 - PubMed
  26. J Hum Hypertens. 2005 Sep;19(9):731-5 - PubMed
  27. Circulation. 2000 Dec 5;102(23):2861-6 - PubMed
  28. Circ Res. 2003 Jun 13;92(11):1254-61 - PubMed
  29. J Hypertens. 2013 Jul;31(7):1281-357 - PubMed
  30. Arterioscler Thromb Vasc Biol. 2005 May;25(5):932-43 - PubMed
  31. Circulation. 2003 Sep 23;108(12):1469-73 - PubMed
  32. J Hypertens. 2012 Jan;30(1):3-16 - PubMed
  33. Blood Press Monit. 2003 Jun;8(3):127-33 - PubMed
  34. Hypertension. 2001 Oct;38(4):922-6 - PubMed
  35. Am J Hypertens. 2010 May;23(5):488-94 - PubMed
  36. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):372 - PubMed
  37. J Hypertens. 2012 Mar;30(3):445-8 - PubMed
  38. J Hypertens. 2011 Jun;29(6):1034-42 - PubMed
  39. Biomed Pharmacother. 2003 Jul-Aug;57(5-6):195-202 - PubMed
  40. Circulation. 2003 Apr 1;107(12):1579-85 - PubMed
  41. Int J Cardiol. 2008 Jul 21;127(3):350-7 - PubMed
  42. Am J Hypertens. 2005 Jan;18(1):50-5 - PubMed
  43. Hypertension. 2001 May;37(5):1236-41 - PubMed

Publication Types